Properties (94)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
ZyCoV-D vaccine technology
Navi_Mumbai-based_company Piramal_Healthcare's_consumer_products_division Zylera_Pharmaceuticals |
| gptkbp:advertising |
Focus on innovation
Focus on accessibility Focus on affordability |
| gptkbp:awards |
Various industry awards
Best Employer Award 2021 Best_Pharmaceutical_Company_Award_2020 |
| gptkbp:CEO |
gptkb:Glenn_Saldanha
Rakesh_K._Kharbanda |
| gptkbp:clinicalTrials |
Collaborates with various research institutions
Conducts clinical trials Conducts clinical trials globally Focus on innovative therapies Conducts clinical research globally Conducts pharmacovigilance studies Develops biosimilars Invests in biotechnology research |
| gptkbp:collaborations |
Collaborates with research institutions
Collaborates with universities Collaborates with healthcare organizations |
| gptkbp:community_engagement |
Engages in community health initiatives
Supports health education programs Participates in health camps |
| gptkbp:employeeCount |
Over 10,000
|
| gptkbp:employees |
Over 10,000
|
| gptkbp:financialPerformance |
Publicly traded company
Revenue growth Profitability Reports quarterly earnings |
| gptkbp:focus_area |
Oncology
Respiratory diseases Diabetes Cardiovascular diseases Dermatology Chronic diseases |
| gptkbp:founded |
1977
|
| gptkbp:founder |
gptkb:Glenmark_Pharmaceuticals_Ltd.
|
| gptkbp:global_presence |
gptkb:Latin_America
gptkb:North_America gptkb:Asia-Pacific Africa Europe Yes |
| gptkbp:headquarters |
gptkb:Mumbai,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Glenmark Pharmaceuticals
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:investmentFocus |
Significant investment in R&D
|
| gptkbp:market |
Emerging markets
Approximately $3 billion (2021) Growing_presence_in_Europe Strong_presence_in_India Growing_presence_in_the_US |
| gptkbp:operates_in |
Over 80 countries
|
| gptkbp:partnerships |
gptkb:Mylan
gptkb:Boehringer_Ingelheim Sanofi Various global pharmaceutical companies |
| gptkbp:patentCitation |
Holds numerous patents
|
| gptkbp:productLine |
Diverse product pipeline
|
| gptkbp:products |
Branded drugs
Active pharmaceutical ingredients (APIs) Generic_drugs |
| gptkbp:regulatoryCompliance |
FDA_approved_products
EMA_approved_products |
| gptkbp:research |
Dr._Ranjit_S._Kharbanda
|
| gptkbp:research_areas |
Pain management
Neurology Infectious diseases Dermatology Cardiovascular |
| gptkbp:research_focus |
Oncology
Respiratory diseases Diabetes Chronic diseases |
| gptkbp:researchAndDevelopment |
Global R&D centers
|
| gptkbp:revenue |
$1.2 billion (2021)
|
| gptkbp:social_responsibility |
Supports local communities
Corporate social responsibility initiatives Environmental sustainability efforts |
| gptkbp:stockExchange |
gptkb:BSE
NSE |
| gptkbp:subsidiary |
gptkb:Glenmark_Life_Sciences
Glenmark_Generics |
| gptkbp:sustainability_initiatives |
Yes
Green manufacturing practices Community health programs Environmental conservation efforts Employee welfare programs Patient access programs |
| gptkbp:website |
www.glenmarkpharma.com
|